Core Viewpoint - Ionis Pharmaceuticals, Inc. is recognized as a strong growth stock with a Moderate Buy consensus on Wall Street, indicating significant upside potential based on analyst targets [1]. Financial Performance - For the full year 2025, Ionis reported revenue of $944 million, reflecting a 34% increase from 2024, driven by the launch of TRYNGOLZA and a $280 million upfront payment from Ono Pharmaceutical [2]. - The company anticipates 2026 revenue to be between $800 million and $825 million on a like-for-like basis, and ended 2025 with $2.7 billion in cash, cash equivalents, and short-term investments [2]. Product Pipeline and Future Prospects - TRYNGOLZA has received priority review for severe hypertriglyceridemia, with a PDUFA date set for June 30, 2026, and the company may update its guidance for the product after Q1 2026 [3]. - TRYNGOLZA generated $108 million in revenue in 2025, with projected U.S. peak sales exceeding $2 billion [3]. - Several catalysts for 2026 include Phase 3 readouts related to CARDIO-TTRansform and the Novartis-partnered pelacarsen in HORIZON, positioning 2026 as a transformational year for the company [3]. Analyst Ratings and Price Targets - Analyst Mani Foroohar maintained an Outperform rating and raised the price target for Ionis to $104 from $102, reflecting confidence in the company's growth potential [4].

Financial Data and Key Metrics Changes - Ionis generated $944 million in revenue for 2025, representing a 34% increase year-over-year [29] - Revenue from commercial products was $436 million (46% of total revenue), while R&D collaborations contributed $508 million (54% of total revenue) [29] - Royalty revenues increased by 11% to $285 million, driven by contributions from Spinraza and Waylivra [31] Business Line Data and Key Metrics Changes - TRYNGOLZA generated $108 million in product sales for 2025, with a 56% increase in Q4 sales compared to Q3 [30] - DAWNZERA achieved $8 million in product sales from its initial months of launch [30] - Olezarsen is projected to exceed $2 billion in annual peak revenue based on positive phase 3 data and strong prescriber demand [23][30] Market Data and Key Metrics Changes - The U.S. market for severe hypertriglyceridemia (sHTG) includes over 1 million individuals at high risk, indicating a significant patient population for Olezarsen [21] - The current payer mix for TRYNGOLZA is approximately 60% commercial and 40% government, with broad access for both clinically diagnosed and genetically confirmed patients [19] Company Strategy and Development Direction - Ionis aims to achieve cash flow breakeven by 2028 while expanding its commercial portfolio through multiple launches [39] - The company is focused on maximizing the potential of its marketed medicines and preparing for additional launches, including Olezarsen for sHTG and Zilganersen for Alexander disease [27][39] - Ionis is committed to maintaining broad patient access while maximizing long-term value realization for its products [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory, highlighting strong commercial momentum and a robust pipeline of innovative therapies [39] - The anticipated approval of Olezarsen is expected to drive significant revenue growth in the fourth quarter of 2026 [32] - Management noted that the company is actively engaging with payers to ensure continued access for patients [46] Other Important Information - The company has a well-capitalized balance sheet with approximately $1.6 billion in cash and investments projected by year-end [37] - Ionis plans to provide detailed revenue guidance for TRYNGOLZA and DAWNZERA at the first quarter earnings call [33] Q&A Session Questions and Answers Question: Can you clarify your guidance regarding sHTG sales and pricing dynamics? - Management confirmed that guidance does not assume significant sHTG sales initially and anticipates a decline in TRYNGOLZA revenues ahead of the sHTG launch, with growth expected post-approval [44][46] Question: What is the reimbursement landscape for FCS and how does it compare to competitors? - Management indicated that there has been no meaningful impact from competitors on TRYNGOLZA demand, and they are focused on maximizing value while ensuring broad access [56][58] Question: What is the expected timeline for the GSK partnered HBV program? - Management stated that GSK plans to present data at EASL in May, with peak sales estimates around $2.5 billion, and Ionis expects to earn tiered royalties from this program [87] Question: How does the launch strategy for Zilganersen compare to other rare diseases? - Management highlighted strong community interest and a focused launch strategy for Zilganersen, with a modest-sized team targeting major leukodystrophy centers [94]